Back to results
US 2022/0033454 A1Published application
Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications
AssigneeAnwita Biosciences, Inc.
InventorsZiyang Zhong, Fan Ye, Jianing Huang, Matthew Siegel, Ji Wang
Life of this patent
Estimating the term…
Abstract
Provided herein are a fusion protein comprising an interleukin-22 domain and an albumin binding domain, and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an inflammatory disease.
Claims49
A fusion protein comprising the amino acid sequence of Formula (I):
- wherein:
- D1 is an interleukin-22 domain and D2 is an albumin binding domain;
- or D1 is an albumin binding domain and D2 is an interleukin-22 domain;
- DC and DN are each independently an interleukin-22 domain, a GLP-2 domain, or an IGF-1 domain;
- L1, LC, and LN are each independently a bond or a peptide linker;
- and
- m and n are each independently an integer of 0 or 1;
- wherein DC and DN are at the C-terminus and N-terminus of the fusion protein, respectively.
5 more elements
2-5. (canceled)
13-15. (canceled)
17-18. (canceled)
24-24. (canceled)
31-33. (canceled)
35-39. (canceled)
42-45. (canceled)
47-50. (canceled)
52-56. (canceled)
58-61. (canceled)
63-67. (canceled)
77-81. (canceled)
83-85. (canceled)
Dependencies are inferred from the claim text.